Aziyo Biologics Valuation

Aziyo Biologics Investor Information

About 70.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.18. Aziyo Biologics had not issued any dividends in recent years. Based on the key indicators related to Aziyo Biologics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Aziyo Biologics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.

Aziyo Biologics Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aziyo Biologics has an asset utilization ratio of 71.45 percent. This suggests that the Company is making $0.71 for each dollar of assets. An increasing asset utilization means that Aziyo Biologics is more efficient with each dollar of assets it utilizes for everyday operations.

Aziyo Biologics Ownership Allocation

The market capitalization of Aziyo Biologics is $23.72 Million. The majority of Aziyo Biologics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aziyo Biologics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aziyo Biologics. Please pay attention to any change in the institutional holdings of Aziyo Biologics as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Aziyo Biologics Profitability Analysis

The company reported the previous year's revenue of 49.19 M. Net Loss for the year was (32.9 M) with profit before overhead, payroll, taxes, and interest of 19.22 M.

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

If you are still planning to invest in Aziyo Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aziyo Biologics' history and understand the potential risks before investing.